AbbVie's Q1 2025: Key Contradictions in Skyrizi, Rinvoq Pricing, and Humira Dynamics

Skyrizi and Rinvoq pricing dynamics and market growth, Humira's market dynamics and impact, Skyrizi and Rinvoq pricing erosion, Humira erosion dynamics are the key contradictions discussed in AbbVie's latest 2025Q1 earnings call.



Immunology Segment Performance:
- AbbVie's immunology segment delivered total revenues of over $6.2 billion, exceeding expectations.
- The growth was attributed to strong performance of Skyrizi and Rinvoq, contributing $5.1 billion in combined sales, and a 65% increase year-over-year.

Oncology and Emerging Franchises:
- Oncology total revenues were $1.6 billion, exceeding expectations.
- Growth was driven by Imbruvica, Venclexta, and emerging solid tumor franchises like Elahere and Teliso-V.

Aesthetics Segment Challenges:
- Aesthetics delivered global sales of $1.1 billion, slightly down 10.2% on an operational basis.
- The decline was attributed to economic headwinds and reduced consumer sentiment impacting market conditions.

Neuroscience and Parkinson's Disease:
- Neuroscience revenues were approximately $2.3 billion, up 17% on an operational basis.
- The growth was driven by strong VRAYLAR performance and the successful launch of VYALEV in Parkinson's disease.